INTRODUCTION
============

Heart failure is one of the leading causes of sudden death in developed countries [@B001]-[@B003]. It is a complex and multi-factorial disease and its pathogenesis is poorly understood. Among the many pathological features of heart failure, the most prominent and widespread in patients and animal models of heart failure is reduced myocardial contractility caused by aberrant Ca^2+^ cycling [@B004],[@B005]. Intracellular Ca^2+^ concentration, the primary determinant of myocardial contractility, is regulated by a group of ion channels, transporters, and pumps in a highly coordinated manner. Upon arrival of electric signals at the sarcolemma, small amounts of Ca^2+^ from the extracellular space enter cardiomyocytes through voltage-gated L-type Ca^2+^ channels. This process, referred to as Ca^2+^-induced Ca^2+^-release, induces Ca^2+^-release from the sarcoplasmic reticulum (SR) through ryanodine receptor 2 (RyR2). The resulting transient increase in intracellular Ca^2+^ concentration drives myocardial contraction. To trigger myocardial relaxation, Ca^2+^ is then removed from the sarcoplasm through Ca^2+^ reuptake into the SR, which is mediated by sarcoplasmic /endoplasmic reticulum Ca^2+^ATPase 2a (SERCA2a) ([Fig. 1](#F0001){ref-type="fig"}).

Defects in RyR2 and SERCA2a functions are partly responsible for impaired contractility in failing hearts. Under heart failing conditions, RyR2 becomes \"leaky\" through its oxidation, nitrosylation, phosphorylation, and altered binding to a variety of RyR2- interacting proteins including calstabins [@B006]. The increased leakiness of RyR2 leads to a depletion of Ca^2+^ from the SR and abnormal depolarization of cardiomyocytes, triggering fatal arrhythmias. Therefore, reducing the leakiness of RyR2 is regarded as an effective therapeutic strategy [@B007]. Furthermore, the expression level of SERCA2a is reduced in failing hearts. The potentiated activity of phospholamban (PLN), an endogenous inhibitor of SERCA2a, through its dephosphorylation further hampers SERCA2a activity. Restoration of SERCA2a activity is therefore a potential treatment target for heart failure.

![Calcium signaling during excitation-contraction coupling. Calcium signaling plays an essential role in cardiac muscle contraction and relaxation. Ca^2+^ entry via LTCC triggers SR Ca^2+^ release through RyR, a process termed calcium-induced calcium release (CICR). CICR causes activation of contraction of myofilaments. SR Ca^2+^ uptake via SERCA2a and extrusion via NCX allow relaxation of myofilaments. CICR, Ca^2+^-induced Ca^2+^ release; LTCC, L-type Ca^2+^ channel; NCX, Na^+^-Ca^2+^ exchanger; PLB, phospholamban; RyR, ryanodine receptor; SERCA2a, sarcoplasmic/endoplasmic reticulum Ca^2+^-ATPase 2a; SR, sarcoplasmic reticulum; T-tubule, transverse tubule.](BMB-46-237-g0001){#F0001}

Adeno-associated virus (AAV)-mediated delivery of SERCA2a has been shown to be safe and effective for treating heart failure in phase 1 and 2 clinical trials and is currently in phase 3 clinical studies. The activity of SERCA2a is regulated by a number of other molecules including PLN, protein phosphatase 1 (PP1), inhibitor-1 (I-1), and protein kinase Cα (PKCα), which together constitute a signaling pathway. Therefore, modulating the activities of these molecules could effectively regulate SERCA2a activity. In this mini-review, we will summarize the approaches used to restore SERCA2a levels and/or activity in animal models of heart failure and in human patients.

SERCA2a
=======

SR Ca^2+^ uptake is reduced in the myocardium of patients with end-stage heart failure [@B008]. In addition, the expression of SERCA2a, which is responsible for SR Ca^2+^ uptake in cardiomyocytes, is decreased at the transcript level [@B009] and the protein level [@B010] in failing hearts. Furthermore, the expression level of SERCA2a appears to play a causal role in regulating cardiac function in failing and non-failing human myocardium [@B011]. The importance of SERCA2a in Ca^2+^ cycling and in the pathophysiology of heart failure has also been shown in SERCA2a knockout (KO) mice. SERCA2a heterozygous mice, in which SERCA2a protein levels are reduced by \~35%, exhibit impaired cardiac functions without showing increased heart failure phenotypes at the baseline [@B012]. Cardiomyocytes isolated from the hearts of SERCA2a heterozygous mice show reduced SR Ca^2+^ load and decreased contractility [@B013]. Under pressure overload, SERCA2a heterozygous mice show accelerated heart failure phenotypes with increased mortality and morbidity, which appears to be caused by decreased systolic and diastolic functions of the hearts [@B014].

Since reduced SERCA2a levels cause heart failure in patients and in model animals, restoration of reduced SERCA2a levels and/or activity is a potential treatment option for heart failure. Adenovirus-mediated gene transfer of SERCA2a improves intracellular Ca^2+^ handling in isolated rat cardiomyocytes in vitro [@B015] and in rat myocardium *in vivo* [@B016]. In addition, adenoviral gene transfer of SERCA2a restores defective intracellular Ca^2+^ handling and contractile function in ventricular cardiomyocytes isolated from patients with end-stage heart failure [@B017]. In a rat model of heart failure, gene transfer of SERCA2a restored reduced SERCA2a levels and concomitant defects in cardiac functions [@B018]. Importantly, this approach significantly improved survival and the energy potential in failing hearts. Inotropic agents such as β-agonists increase contractile functions at the expense of increased mortality and decreased metabolism. The β-agonist-mediated increase in mortality is thought to be due to increased intracellular Ca^2+^ at diastole, which leads to activation of pro-apoptotic and pro-hypertrophic signals, which may increase the incidence of ventricular arrhythmia. Therefore, β-blockers are currently being used for the treatment of heart failure despite their negative inotropic effects. Unlike these agents, gene transfer of SERCA2a is inotropic in its effects on contractility and yet improves metabolism and survival by normalizing intracellular Ca^2+^ level at diastole.

The above studies suggest that gene transfer of SERCA2a could be a promising modality for the treatment of heart failure. In one study, volume overload-induced heart failure was mimicked by inducing mitral regurgitation in pigs followed by intracoronary delivery of recombinant adeno-associated virus (rAAV) carrying SERCA2a. Two months later, SERCA2a gene delivery significantly restored contractile parameters and reversed the adverse left ventricular remodeling in these pigs [@B019]. AAV-mediated delivery of SERCA2a also improves cardiac functions in sheep with pacing-induced heart failure [@B020]. In addition, gene delivery of SERCA2a reduces the incidence of ventricular arrhythmias after ischemia-reperfusion in pigs [@B021]. This beneficial effect may be attributed to the modulation of post-ischemic Ca^2+^ overload by SERCA2a. Based on the success observed with large animal models of heart failure, gene delivery of SERCA2a was attempted in clinical trials, including a phase 1 trial of a single intracoronary infusion of AAV1 carrying SERCA2a to patients with advanced heart failure. Several of the treated patients showed significant improvements in a number of parameters, while two patients who showed no improvements had pre-existing anti-AAV1 neutralizing antibodies [@B022]. In addition, 39 patients without neutralizing antibodies were similarly treated in a phase 2 trial, which showed that treatment with AAV1 carrying SERCA2a was beneficial and was not associated with serious safety issues [@B023]. This approach has now moved on to phase 3 trials with a large cohort (∼400) of patients.

As described above, restoration of reduced SERCA2a levels in failing hearts using gene transfer approaches is effective in improving cardiac deficits in human patients. SERCA2a is subject to a variety of post-translational modifications, which affect its enzymatic activity and/or stability. Recently, our group showed that SERCA2a is SUMO (Small Ubiquitin-like MOdifier)-ylated at two lysine residues and that this SUMOylation is essential for preserving the activity and stability of SERCA2a [@B024]. Notably, SUMOylation of SERCA2a is specific to SUMO1, and is not observed with SUMO2 or SUMO3. The levels of SUMO1 and the extent of SUMOylation of SERCA2a are greatly reduced in failing hearts. Gene delivery of SUMO1 rescues cardiac dysfunction, whereas shRNA-mediated down-regulation of SUMO1 decreases SERCA2a activity and accelerates cardiac dysfunction induced by pressure overload in mice. Although the exact mechanisms underlying the beneficial effects of SUMOylation are unclear, overexpression of SUMO1 via gene delivery appears to be as efficient as the overexpression of SERCA2a itself in improving cardiac function.

In conclusion, the restoration of SERCA2a levels or activity through gene delivery-mediated expression of SERCA2a or SUMO1, respectively, can be an efficient modality for the treatment of heart failure.

PHOSPHOLAMBAN
=============

SERCA2a activity is directly modulated by a 52-amino acid endogenous inhibitor, phospholamban (PLN). The inhibitory effect of PLN on SERCA2a activity was first revealed using transgenic animal models. Cardiac-specific overexpression of PLN inhibited SR Ca^2+^ uptake and reduced systolic Ca^2+^ levels, contractile parameters, and basal systolic function in mice [@B025]. In contrast, PLN knockout (KO) mice exhibited enhanced Ca^2+^ cycling and myocardial contractility with no gross developmental abnormalities. The elevated contractile parameters are associated with increased affinity of SERCA2a for Ca^2+^ [@B026]. Furthermore, comparative analyses with wild type and heterozygous and homozygous PLN KO mice revealed that relative PLN levels correlate well with the affinity of SERCA2a for Ca^2+^ and with the rates of relaxation and contraction of isolated cardiomyocytes [@B027]. These findings suggest that the PLN level may determine the parallel outcomes in SR function and cardiac contractility in mice.

Furthermore, studies have shown that mutations in human PLN result in dilated cardiomyopathy. A dominant Arg→Cys mutation at residue 9 (R9C) in PLN was identified in a patient with inherited dilated cardiomyopathy (Schmitt, 2003). PLN^R9C^ indirectly inhibits SERCA2a activity by inhibiting cAMP-dependent protein kinase (PKA)-mediated phosphorylation of wild type PLN. Furthermore, PKA-mediated phosphorylation of PLN at Ser16 decreases its inhibitory activity. It appears that the chronic inhibition of SERCA2a by PLN^R9C^ leads to dilated cardiomyopathy and premature death in families carrying this mutation. In another genetic study, a truncated PLN protein caused by the substitution of Leu39 with a termination codon (L39stop) was identified in individuals of two families with hereditary heart failure [@B028]. Individuals homozygous for this mutation developed dilated cardiomyopathy and heart failure, whereas heterozygous individuals exhibited cardiac hypertrophy without overt heart failure. These observations were recapitulated in transgenic (Tg) mice with cardiac-specific expression of PLN^R9C^. PLN^L39stop^ was neither functional nor dominant-negative when expressed in cardiomyocytes and HEK293 cells. Moreover, PLN^L39stop^ was undetectable in the myocardium; thus, it could be viewed as a null mutation. While the PLN null mutation is beneficial in mice, it is detrimental in humans, resulting in severe heart failure. It is likely that chronic stimulation of human heart tissue resulting from the absence of functional PLN causes or accelerates the progression of heart failure. Taken together, these studies suggest that SERCA activity must be maintained within a narrow range to promote stable heart function, and that PLN may have a role in this maintenance.

![SERCA2a activity and calcium handling in heart failure. The dysregulation of SERCA2a is a hallmark of heart failure. Reduction in SR Ca^2+^ uptake results in systolic dysfunction as well as increased cytosolic Ca^2+^ level and susceptibility to apoptosis. In heart failure, SERCA2a activity and expression are decreased via negative regulation by upstream modulators. I-1, protein phosphatase inhibitor 1; PKCα, the α isotype of protein kinase C; PLB, phospholamban; PP1, protein phosphatase 1; SERCA2a, sarcoplasmic/endoplasmic reticulum Ca^2+^-ATPase 2a; SUMO, small ubiquitin- like modifier; RyR, ryanodine receptor.](BMB-46-237-g0002){#F0002}

The activity of PLN is critically regulated by phosphorylation at two residues; Ser16 by cAMP-dependent protein kinase (PKA), and Thr17 by Ca^2+^-CaM-dependent protein kinase (CaMK). Both of these phosphorylations can be reversed by protein phosphatase 1 (PP1). PLN is in dynamic equilibrium between monomeric and pentameric states. When phosphorylated, PLN appears to mainly form a pentamer, which is inactive or at least less active in inhibiting SERCA2a activity than the monomer. In contrast, the dephosphorylated form of PLN exists mainly as a monomer, which can bind to and inhibit SERCA2a activity.

In failing hearts of patients and animals, both the level and activity of SERCA2a are lower than in normal hearts, and this has been suggested to contribute to cardiac dysfunction [@B029]. In addition, during cardiac failure, the level of PLN is unaffected, but PLN phosphorylation is lower, which causes further loss of SERCA2a activity. [Fig. 2](#F0002){ref-type="fig"} shows the signaling pathway involved in the decrease in SERCA2a activity in failing hearts. Decreased phosphorylation of PLN in failing hearts is mainly caused by increased PP1 activity. Therefore, inhibiting PP1-mediated dephosphorylation of PLN may be a strategy to restore SERCA2a activity during heart failure. Previously, our group tested this hypothesis using decoy peptides [@B030]. We synthesized a 9-mer peptide that exactly matched the nine amino acids of the loop region (aa 14-22), except that the Ser residue was replaced by Glu ([Fig. 3](#F0003){ref-type="fig"}). This peptide, coupled to a cell-permeable peptide TAT, was referred to as ψPLN-SE. It mimicked the loop region of PLN phosphorylated by PKA, thereby serving as a decoy for PP1. Treatment of cardiomyocytes with phorbol 12-myristate 13-acetate (PMA) significantly reduced phosphorylation of PLN through activation of PKCα (see [Fig. 2](#F0002){ref-type="fig"}). As expected, ψPLN-SE significantly restored the phosphorylation of PLN in cardiomyocytes treated with PMA. In an *ex vivo* set up, ischemia-reperfusion resulted in severe loss of cardiac function and reduced phosphorylation of PLN. Addition of ψPLN-SE at the time of reperfusion significantly restored cardiac function and increased phosphorylation levels of PLN *ex vivo* [@B030] and *in vivo* in mice (Oh *et al*., unpublished data). Collectively, our data suggest that ψPLN-SE improves functional recovery after ischemia-reperfusion at least in part by increasing the phosphorylation level of PLN.

![Design of decoy peptides. The \"L-shaped\" structure of monomeric PLB is composed of a cytoplasmic helix, a connecting short loop, and a transmembrane helix. Blue box, ψPLB-SE was derived from the nine amino acids that compose the connecting loop. In the decoy peptide, the serine residue was replaced with a glutamine to mimic the peptide in its phosphorylated state (shown in green). The peptide was conjugated via a disulfide bond at the amino-termini to the cell penetrating peptide TAT (YG-RKKRRQRRR) to facilitate uptake of the peptide into cells.](BMB-46-237-g0003){#F0003}

PROTEIN PHOSPHATASE 1/INHIBITOR-1
=================================

PP1 was first identified as the phosphatase responsible for dephosphorylating PLN in the myocardium [@B031],[@B032]. PP1 activity is 2-fold higher in failing human hearts than in non-failing hearts [@B033]. Further insights into the role of PP1 during heart failure were made through animal studies using Tg mice. Cardiac-specific overexpression of PP1 in Tg mice leads to cardiac dysfunction, dilated cardiomyopathy, and premature mortality, which are associated with decreases in the phosphorylation of PLN [@B034]. As shown above, inhibiting PP1-mediated dephosphorylation of PLN can be an efficient strategy to activate SERCA2a. However, this strategy may have limitations as PP1 is involved in a variety of biological processes in many organs. Thus, careful arrangements for targeted inhibition of PP1 specifically in hearts are needed.

I-1 is an endogenous inhibitor of PP1. Ablation of I-1 results in increased PP1 activity and decreased phosphorylation of PLN. Moreover, basal cardiac functions are severely depressed in I-1 KO mice [@B034]. In contrast, overexpression of I-1 in heart tissue engineered from neonatal rat cardiomyocytes or adult rat cardiomyocytes results in increased cell shortening and a concomitant increase in PLN phosphorylation [@B035]. Both PLN phosphorylation and cardiac contractility are elevated at the cellular and organism levels in Tg mice with cardiac-specific overexpression of constitutively active truncated I-1 (I-1c) [@B036]. Notably, adenovirus-mediated acute expression of I-1c restores cardiac function and partially reverses remodeling of the pre-established heart failure in these mice. The role of I-1 has also been evaluated by inducing the expression of I-1c in adult mouse hearts after an ischemic insult. In that study, overexpression of I-1c resulted in a significant improvement in cardiac function and associated increases in PLN phosphorylation and SERCA2a activity. Furthermore, increased I-1 activity significantly attenuated ischemia-reperfusion injury via suppression of endoplasmic reticulum stress responses [@B037]. Collectively, these results indicate that I-1 is an endogenous inotropic molecule that inhibits PP1; thus, overexpression of I-1 may be a valuable therapy for the treatment of heart failure.

PKCα
====

Isoproterenol (ISO), a β-agonist, increases cardiac contractility via the activation of protein kinase A (PKA). A number of studies have shown that the inotropic effect of ISO is exerted through PKA-mediated phosphorylation of I-1 [@B038],[@B039]. In addition, I-1 becomes a potent inhibitor of PP1 when it is phosphorylated at Thr35 by PKA [@B040].

I-1 contains PKCα phosphorylation sites, Ser67 and Thr75. The role of PKCα in cardiac function was controversial until the Molkentin group showed that PKCα is associated with depressed contractility [@B041]. Overexpression of PKCα increases PP1 activity by decreasing the interaction of I-1 with PP1 via an increase in the phosphorylation of I-1 at Ser67. Accordingly, PKCα KO hearts exhibit increased contractility and decreased phosphorylation of I-1 at Ser67. In addition, Thr75 is another primary PKCα phosphorylation site in I-1 [@B042]. Constitutively phosphorylated forms of I-1 containing S67D and/or T75D substitutions significantly increase PP1 activity and decrease contractility by decreasing SERCA2a activity in isolated cardiomyocytes. However, the effects of these mutations are not additive. Notably, activation of the PKA signaling pathway only marginally reverses the adverse effects of the constitutively phosphorylated forms of I-1 on contractility [@B043]. Therefore, I-1 appears to function at the intersection of PKA and PKC signaling pathways.

Inhibitors of conventional PKC isotypes such as Ro-31-8220, Ro-32-0432, and ruboxitaurin (LY333531) have been vigorously tested for their effects in different rodent models of heart failure [@B044]. The importance of PKCα was further supported by a finding that ruboxitaurin increases cardiac contractility in wild type and PKCβγ KO mice, but not in PKCα KO mice [@B045]. In a pig model of heart failure induced by occlusion of the left anterior descending artery, administration of ruboxitaurin resulted in a significantly better recovery of cardiac contractility and an increase in cardiac ejection fraction and cardiac output [@B046]. These results suggest that inhibition of PKCα represents a promising approach for the treatment of heart failure.

CONCLUSION
==========

As summarized in [Fig. 2](#F0002){ref-type="fig"}, activation of PKCα triggers a signaling pathway that leads to decreased SERCA2a activity in the failing heart. Normalization of SERCA2a activity through modulation of this signaling pathway or elevation/modification of SERCA2a itself could be a valid strategy for the treatment of heart failure. Gene delivery of *SERCA2a* has advanced to phase 3 clinical trials. Other approaches were also found to be effective in pre-clinical studies but will require clinical trials to elucidate their efficacy in treating heart failure. In addition to the molecules shown in [Fig. 2](#F0002){ref-type="fig"}, other molecules such as HSP20 and HAX1 are also involved in the regulation of SERCA2a activity. Taken together, the results from various laboratories and clinics show that the regulation of SERCA2a expression is complex. Further in-depth research into the SERCA2a regulatome will hopefully reveal alternative approaches for the modulation of cardiac contractility.
